GENEDRIVE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.625 GBX | -8.16% |
|
-4.26% | -30.77% |
| Apr. 24 | Genedrive enters clinical trial deal in US for MT-RNR1 US approval | AN |
| Apr. 03 | FTSE 100 up thanks to US economic data | AN |
| Sales 2022 | 49K 61.32K | Sales 2023 | 55K 68.82K | Capitalization | 17.33M 21.69M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -5.01M | Net income 2023 | -5M -6.26M | EV / Sales 2022 | 237 x |
| Net cash position 2022 | 4.57M 5.72M | Net cash position 2023 | 2.36M 2.95M | EV / Sales 2023 | 272 x |
| P/E ratio 2022 |
-3.18
x | P/E ratio 2023 |
-3.18
x | Employees | 43 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -8.16% | ||
| 1 week | -2.17% | ||
| Current month | +66.67% | ||
| 1 month | +50.00% | ||
| 3 months | -13.46% | ||
| 6 months | -39.84% | ||
| Current year | -30.77% |
1 week
5.05
7.25
1 month
2.5610.00
Current year
2.5610.00
1 year
2.5625.90
3 years
2.5695.98
5 years
2.56302.60
10 years
2.56342.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Cheek
CEO | Chief Executive Officer | 57 | 23-09-10 |
Russell Shaw
DFI | Director of Finance/CFO | 45 | 22-04-06 |
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Chris Yates
BRD | Director/Board Member | 50 | 18-08-21 |
Thomas Lindsay
BRD | Director/Board Member | 66 | 18-04-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 5.625 | -8.16% | 3,024,427 |
| 24-04-24 | 6.125 | +8.89% | 5,461,201 |
| 24-04-23 | 5.625 | -4.26% | 744,960 |
| 24-04-22 | 5.875 | 0.00% | 286,779 |
| 24-04-19 | 5.875 | 0.00% | 602,491 |
Delayed Quote London S.E., April 25, 2024 at 11:35 am EDT
More quotes
genedrive plc is a United Kingdom-based patient molecular diagnostics company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company offers products, including Genedrive MT-RNR1 ID Kit and Genedrive COV19-ID Kit. Genedrive MT-RNR1 ID Kit is a rapid genetic test in an emergency neonatal care setting. It has developed tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of hepatitis c virus (HCV), infection prior to drug administration, pathogen detection of biological military threats, and a point-of-care for COVID-19 detection system for us in areas such as healthcare, workplace screening, travel requirements, or confirmation of antigen tests.
Calendar
2024-11-18
- Q4 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.77% | 10.9M | |
| -15.34% | 19.18B | |
| -46.15% | 2.73B | |
| +14.09% | 1.84B | |
| -3.39% | 1.61B | |
| +23.19% | 1.18B | |
| -10.58% | 1B | |
| -21.72% | 898M | |
| -12.15% | 710M | |
| -17.56% | 694M |
- Stock Market
- Equities
- EHP Stock
